AR006401A1 - Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos. - Google Patents

Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.

Info

Publication number
AR006401A1
AR006401A1 ARP970101212A ARP970101212A AR006401A1 AR 006401 A1 AR006401 A1 AR 006401A1 AR P970101212 A ARP970101212 A AR P970101212A AR P970101212 A ARP970101212 A AR P970101212A AR 006401 A1 AR006401 A1 AR 006401A1
Authority
AR
Argentina
Prior art keywords
compounds
processes
therapy
manufacture
preparation
Prior art date
Application number
ARP970101212A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606508.1A external-priority patent/GB9606508D0/en
Priority claimed from GBGB9623001.6A external-priority patent/GB9623001D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR006401A1 publication Critical patent/AR006401A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se refiere a compuestos de pirrolopirrolona de fórmula (I) que sirven, entre otros, para el tratamiento de la bronquitis crónica. Comprende tambiénuna composición farmacéutica que contiene dichos compuestos, y el uso de los mismos en lafabri cación de un medicamento y en terapia. Otro aspecto es unproceso para la preparación de los compuestos. También se revelan compuestos intermediarios para dicho proceso.
ARP970101212A 1996-03-28 1997-03-26 Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos. AR006401A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9606508.1A GB9606508D0 (en) 1996-03-28 1996-03-28 Chemical componds
GBGB9623001.6A GB9623001D0 (en) 1996-11-05 1996-11-05 Chemical compounds

Publications (1)

Publication Number Publication Date
AR006401A1 true AR006401A1 (es) 1999-08-25

Family

ID=26309008

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101212A AR006401A1 (es) 1996-03-28 1997-03-26 Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.

Country Status (30)

Country Link
US (3) US5994344A (es)
EP (1) EP0891362B1 (es)
JP (1) JP4118337B2 (es)
KR (1) KR20000005039A (es)
CN (1) CN1067075C (es)
AP (1) AP823A (es)
AR (1) AR006401A1 (es)
AT (1) ATE261969T1 (es)
AU (1) AU726649B2 (es)
BR (1) BR9708449A (es)
CA (1) CA2250209A1 (es)
CO (1) CO4790152A1 (es)
CZ (1) CZ309798A3 (es)
DE (1) DE69728139T2 (es)
DK (1) DK0891362T3 (es)
EA (1) EA001437B1 (es)
EE (1) EE9800335A (es)
ES (1) ES2217404T3 (es)
HU (1) HUP9900567A3 (es)
IL (1) IL125859A0 (es)
IS (1) IS4837A (es)
NO (1) NO984470L (es)
NZ (1) NZ331490A (es)
PE (1) PE55298A1 (es)
PL (1) PL329153A1 (es)
PT (1) PT891362E (es)
SK (1) SK132498A3 (es)
TR (1) TR199801935T2 (es)
WO (1) WO1997036903A1 (es)
YU (1) YU41198A (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9719189D0 (en) * 1997-09-09 1997-11-12 Glaxo Group Ltd New therapeutic method
PE107899A1 (es) * 1997-09-09 1999-11-17 Glaxo Group Ltd Derivados de pirrolopirrolona como inhibidores de elastasa leucocitaria
GB9719172D0 (en) * 1997-09-09 1997-11-12 Glaxo Group Ltd Compounds
GB9719187D0 (en) * 1997-09-09 1997-11-12 Glaxo Group Ltd Compounds
GB9821199D0 (en) * 1998-09-30 1998-11-25 Glaxo Group Ltd Chemical compounds
GB9905418D0 (en) * 1999-03-09 1999-05-05 Glaxo Group Ltd Process
US20060100231A1 (en) * 2003-03-10 2006-05-11 Hetero Drugs Limited Amorphous clopidogrel hydrogen sulfate
MXPA05009771A (es) 2003-03-14 2005-10-26 Ono Pharmaceutical Co Derivados heterociclicos que contienen nitrogeno y medicamentos que los contienen como el ingrediente activo.
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US7692037B2 (en) * 2004-09-02 2010-04-06 Eastman Chemical Company Optimized liquid-phase oxidation
GB2418427A (en) 2004-09-02 2006-03-29 Univ Cambridge Tech Ligands for G-protein coupled receptors
RU2409565C2 (ru) 2004-09-13 2011-01-20 Оно Фармасьютикал Ко., Лтд. Азотистые гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента
GB0512238D0 (en) * 2005-06-15 2005-07-27 Univ Cambridge Tech Anti-inflammatory agents
US8003642B2 (en) 2006-03-10 2011-08-23 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
MX348481B (es) * 2007-04-23 2017-06-15 Siga Tech Inc Productos quimicos, composiciones y metodos para tratamiento y prevencion de infecciones de virus orthopox y enfermedades asociadas.
BRPI0820171B8 (pt) 2007-11-16 2021-05-25 Rigel Pharmaceuticals Inc compostos de carboxamida, sulfonamida e amina para distúrbios metabólicos, composição farmacêutica, e, uso dos mesmos
US8129390B2 (en) 2007-12-12 2012-03-06 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds and methods for using the same
WO2009132136A1 (en) 2008-04-23 2009-10-29 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
WO2014095700A1 (en) * 2012-12-18 2014-06-26 Chiesi Farmaceutici S.P.A. Novel compounds
JP2023500182A (ja) 2019-09-17 2023-01-05 メレオ バイオファーマ ４ リミテッド 移植片拒絶反応、閉塞性細気管支炎症候群、及び移植片対宿主病の治療に使用するためのアルベレスタット
IL297211A (en) 2020-04-16 2022-12-01 Mereo Biopharma 4 Ltd Methods involving the neutrophil elastase inhibitor albalstat for the treatment of respiratory disease mediated by alpha-1 antitrypsin deficiency
TW202325294A (zh) 2021-10-20 2023-07-01 英商梅瑞奧生物製藥４有限公司 用於治療纖維化之嗜中性球彈性蛋白酶抑制劑

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2932650A (en) * 1957-11-19 1960-04-12 Arthur C Cope 2-6-diazabicyclo (3. 3. 0) octanes
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
GB9211783D0 (en) * 1992-06-04 1992-07-15 Ici Plc Amide derivatives
GB9402680D0 (en) * 1994-02-11 1994-04-06 Zeneca Ltd Pyrrolidine derivatives
US5610296A (en) * 1994-12-05 1997-03-11 G. D. Searle & Co. Process for the preparation of amidino phenyl pyrrolidine beta-alanine urea analogs

Also Published As

Publication number Publication date
EA001437B1 (ru) 2001-02-26
NZ331490A (en) 2000-06-23
CA2250209A1 (en) 1997-10-09
US5994344A (en) 1999-11-30
IL125859A0 (en) 1999-04-11
US6215002B1 (en) 2001-04-10
JP2000507950A (ja) 2000-06-27
IS4837A (is) 1998-08-28
JP4118337B2 (ja) 2008-07-16
US6057457A (en) 2000-05-02
NO984470D0 (no) 1998-09-25
PT891362E (pt) 2004-08-31
AU726649B2 (en) 2000-11-16
CO4790152A1 (es) 1999-05-31
DK0891362T3 (da) 2004-07-12
TR199801935T2 (xx) 1999-03-22
BR9708449A (pt) 1999-08-03
HUP9900567A2 (hu) 1999-06-28
WO1997036903A1 (en) 1997-10-09
DE69728139T2 (de) 2004-10-21
EP0891362B1 (en) 2004-03-17
CZ309798A3 (cs) 1999-02-17
CN1067075C (zh) 2001-06-13
SK132498A3 (en) 1999-08-06
ATE261969T1 (de) 2004-04-15
AP823A (en) 2000-04-25
HUP9900567A3 (en) 2001-02-28
EE9800335A (et) 1999-04-15
EA199800773A1 (ru) 1999-06-24
ES2217404T3 (es) 2004-11-01
CN1219935A (zh) 1999-06-16
NO984470L (no) 1998-11-25
KR20000005039A (ko) 2000-01-25
AU2291797A (en) 1997-10-22
AP9801351A0 (en) 1998-09-30
PL329153A1 (en) 1999-03-15
YU41198A (sh) 1999-09-27
EP0891362A1 (en) 1999-01-20
DE69728139D1 (de) 2004-04-22
PE55298A1 (es) 1998-09-19

Similar Documents

Publication Publication Date Title
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
MX9301929A (es) Derivados de pirimidina y procedimientos para su preparacion.
PT90764A (pt) Processo para a preparacaode um produto farmaceutico compreendendo um estrogenio e um anti-estrigenio e de composicoes farmaceuticas que os contem
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
RU94029662A (ru) Фосфонооксиметиловые эфиры производных таксана, фармацевтическая композиция, способы лечения
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
AR003938A1 (es) Compuestos triciclicos de urea utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proteoliticas, composicionfarmaceutica, y el uso de los mismos para la preparacion de medicamentos.
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
SE9904505D0 (sv) Novel compounds
AR012294A1 (es) Derivados de sulfonamida, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen, uso de dichos derivados para lapreparacion de un medicamento.
MX9300407A (es) Derivados azabiciclicos usados en la fabricacion de medicamentos, composiciones que los contienen y procedimiento para su preparacion.
DK0781281T3 (da) Beta-Carbolinderivater som melatonin-agonister, fremgangsmåder til fremstilling deraf og deres anvendelse som lægemiddel
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
AR019496A1 (es) Azalidas de 13 miembros, composiciones farmaceuticas, uso en la preparacion de medicamentos y preparacion de los mismos
DE69034226D1 (de) Herstellungsverfahren von Huperzine A und deren Analogen und Verbindungen nützlich dazu
PT98371A (pt) Processo para a preparacao de derivados 6-alcoxi de arabinofuranosil-guanina e de composicoes farmaceuticas que os contem
ES2160680T3 (es) Utilizacion de un antagonista de sustancia p en una composicion farmaceutica.
BR9814498A (pt) Processo para o tratamento de obesidade em um humano necessitando de tal tratamento, composto, uso do mesmo, produto, e, composição farmacêutica
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
IL112059A (en) Transdermal therapeutic composition containing a deuterated active substance with penetration-enhancing effect
AU623805B2 (en) New use of anti-progestomimetic compounds
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция

Legal Events

Date Code Title Description
FA Abandonment or withdrawal